Improving Methadone Dose Confirmation: Innovative Approaches and Challenges of CFR Part 2

Friday, April 24, 2026

10:45 AM - 12:00 PM PT

Location: Balboa, Level 2

Presenter(s)

William M. Garneau, MD, MPH, MHS

Assistant Professor of Medicine
Johns Hopkins School of Medicine
Baltimore, Maryland

Slides
Malik Burnett, MD, MBA, MPH

Medical Director
REACH Health Services
Laurel, Maryland
Sophia Peng, MD FASAM

Assistant Professor of Medicine
Rush University Medical Center
chicago, Illinois
Aaron Ferguson, BSW

Harm Reduction Coordinator - Leadership Team-Methadone Liaison
National Survivors Union - Community Medical Services
Austin, Texas
NG

Nicole M. Gastala, MD, MS

Chief of Integrated Behavioral Health and Addiction
UI Health Mile Square Health Center - University of Illinois Chicago
Chicago, Illinois

Non-presenting author(s)

Maia Gottlieb, MPH

Behavioral Health Lead
CRISP
Washington, District of Columbia
Corrina Klein, B.A.

MD/MPH Student
Johns Hopkins University
Baltimore, Maryland

Join us for an engaging and interactive workshop that addresses the opportunities for integration of methadone dosage verification within health information exchange systems. Participants will explore real-world challenges and collaborative solutions to enhance continuity of care for individuals transitioning between hospital and community treatment, ultimately improving health outcomes and addressing disparities in opioid treatment.

Learning Objectives:

Learners will be able to:

Upon completion, participant will be able to describe the legal status of methadone treatment data for clinical use
Upon completion, participant will be able to evaluate innovative approaches to improve continuity of care for methadone treatment across health care settings and develop solutions to improve care at a local level
Upon completion, participant will be able to appraise the clinical benefits and unintended legal consequences of OTP integration with PDMP data.

Disclosure(s):

William M. Garneau, MD, MPH, MHS: Abbott Laboratories: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Astrazeneca Pharmaceuticals LP: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Danaher: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Eli Lilly and Company: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Gilead Sciences, Inc.: Consultant/Advisory Board (Ongoing); Intuitive Surgical Inc.: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); IQVIA: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); Premier, Inc.: Consultant/Advisory Board (Ongoing); Stryker Corporation: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing); UnitedHealth Group, Inc.: Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing)

Malik Burnett, MD, MBA, MPH: No financial relationships to disclose

Sophia Peng, MD FASAM: No financial relationships to disclose

Nicole M. Gastala, MD, MS: No financial relationships to disclose

Maia Gottlieb, MPH: No financial relationships to disclose

Corrina Klein, B.A.: No financial relationships to disclose